ProMIS Neurosciences (PMN)
NASDAQ:PMN
Want to see PMN full AI Analyst Report?
PMN Stock Chart & Stats
$8.12
-$0.04(-3.74%)
At close: 4:00 PM EST
$8.12
-$0.04(-3.74%)
Day’s Range― - ―
52-Week Range$6.27 - $39.75
Previous CloseN/A
Volume32.49K
Average Volume (3M)819.50K
Market Cap
$26.47M
Enterprise Value$9.37M
Total Cash (Recent Filing)$6.15M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.32
Next Earnings
May 18, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.11
Shares Outstanding2,152,397
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$35.00Price Target Upside331.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-6.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
PIPE Financing / Extended RunwayA sizeable $75M PIPE that extends cash runway into 2028 materially reduces near‑term funding risk and funds completion of Phase 1b and six‑/12‑month readouts. Structurally, this financing enables milestone delivery rather than relying solely on uncertain future raises.
Focused Antibody Therapeutic PlatformA clear, specialized R&D focus on antibody candidates that target disease-driving toxic protein species creates a repeatable discovery/development model. This platform alignment supports focused clinical programs, potential portfolio expansion, and partnering/licensing optionality over the medium term.
Low Reported Financial LeverageMinimal reported debt reduces fixed financial obligations and interest burden, preserving flexibility to prioritize R&D spending. Combined with the PIPE, a low‑debt capital structure lowers bankruptcy risk and supports strategic decisions without heavy servicing costs.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the business is structurally reliant on external capital to sustain development. This dependency increases financing risk, potential dilution over time, and constrains long‑term planning if future raises or milestones falter.
Negative Shareholders' EquityRepeated negative equity reflects accumulated losses and eroded capital cushions. This weakens financial flexibility, may limit access to credit or collaborative funding, and increases vulnerability to adverse outcomes or unexpected expenses over the medium term.
No Recurring Revenue / Pre‑commercial StatusAbsence of product revenue means the company's long‑term viability hinges on successful clinical development and commercialization, which are binary and multi‑year. Lack of revenue increases sensitivity to trial outcomes and makes strategic progress contingent on external funding and partnerships.
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $6.27 and its highest was $39.75 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $26.47M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is May 18, 2026 which is in 30 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on Mar 25, 2026. The company reported -$4.11 earnings per share for the quarter, beating the consensus estimate of -$4.66 by $0.55.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -1.06.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 2,152,397 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -$4.11 in its last earnings report, beating expectations of -$4.66. Following the earnings report the stock price went down -9.065%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ProMIS Neurosciences
ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes its proprietary technology platform to selectively target misfolded proteins implicated in these diseases, aiming to develop disease-modifying treatments. ProMIS Neurosciences operates primarily in the biotechnology and pharmaceutical sectors, leveraging advanced scientific research to address unmet medical needs in neurodegenerative conditions.
PMN Stock 12 Month Forecast
Average Price Target
$35.00
▲(331.03% Upside)